PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Cyclophosphamide

Drugs in development · updated 30 October 2026

Cyclophosphamide: clinical trials and development status

Other names and codes: Cytoxan, Endoxan, Frindovyx

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Cyclophosphamide is in 882 active clinical trials (recruiting or ongoing, phases I–III) for 291 diseases. The most advanced phase is III.

882Active trials
IIIMost advanced phase
291Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Cyclophosphamide and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 291 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Precursor lymphoblastic lymphoma/leukemiaIII88NCT03007147
Breast neoplasmIII73NCT06144944
Diffuse large B-cell lymphomaIII72NCT06717347
Acute myeloid leukemiaIII58NCT05457556
Multiple myelomaIII50NCT06615479
Non-Hodgkin lymphomaIII49NCT04529772
Burkitt lymphomaIII47NCT02101853
Myelodysplastic SyndromesIII45NCT05457556
LymphomaIII43NCT04529772
B-cell lymphomaIII41NCT04529772
Triple-negative breast neoplasmIII40NCT06966700
Follicular lymphomaIII39NCT06091254
Chronic lymphocytic leukemiaIII36NCT02048813
Hematologic neoplasmII–III30NCT03818334
LeukemiaIII29NCT04547049
Graft-versus-host diseaseIII28NCT06615050
Ovarian neoplasmIII28NCT04520074
NeoplasmIII26NCT04529772
Hodgkin lymphomaIII23NCT04638790
NeuroblastomaIII22NCT06172296
Acute biphenotypic leukaemiaIII19NCT03007147
Lymphoma, B-Cell, Marginal ZoneII–III18NCT04799275
Precursor T-cell lymphoblastic leukemiaIII17NCT02112916
MetastasisIII14NCT06072612
RhabdomyosarcomaIII13NCT02567435
Autoimmune diseaseII–III12NCT06154252
MedulloblastomaIII12NCT05382338
Precursor B-cell lymphoblastic leukemiaIII12NCT03914625
Systemic sclerodermaIII12NCT07335562
MyositisII–III11NCT06154252

Everything on Cyclophosphamide

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch